Laureen D Hachem1, Christopher S Ahuja2,1, Michael G Fehlings2,1,3,4,5,6. 1. b Institute of Medical Science, University of Toronto , Toronto , ONT , Canada. 2. a Division of Neurosurgery, Department of Surgery , University of Toronto , Toronto , ONT , Canada. 3. c McEwen Centre for Regenerative Medicine, UHN , University of Toronto , Toronto , ONT , Canada. 4. d Department of Surgery , University of Toronto , Toronto , ONT , Canada. 5. e Spine Program , University of Toronto , Toronto , ONT , Canada. 6. f McLaughlin Center in Molecular Medicine , University of Toronto , Toronto , ONT , Canada.
Abstract
CONTEXT: Spinal cord injury (SCI) is a devastating condition that can lead to significant neurological impairment and reduced quality of life. Despite advancements in our understanding of the pathophysiology and secondary injury mechanisms involved in SCI, there are currently very few effective treatments for this condition. The field, however, is rapidly changing as new treatments are developed and key discoveries are made. METHODS: In this review, we outline the pathophysiology, management, and long-term rehabilitation of individuals with traumatic SCI. We also provide an in-depth overview of emerging therapies along the spectrum of the translational pipeline. EVIDENCE SYNTHESIS: The concept of "time is spine" refers to the concept which emphasizes the importance of early transfer to specialized centers, early decompressive surgery, and early delivery of other treatments (e.g. blood pressure augmentation, methylprednisolone) to affect long-term outcomes. Another important evolution in management has been the recognition and prevention of the chronic complications of SCI including respiratory compromise, bladder dysfunction, Charcot joints, and pressure sores through directed interventions along with early integration of physical rehabilitation and mobilization. There have also been significant advances in neuroprotective and neuroregenerative strategies for SCI, many of which are actively in clinical trial including riluzole, Cethrin, stem cell transplantation, and the use of functional electrical stimulation. CONCLUSION: Pharmacologic treatments, cell-based therapies, and other technology-driven interventions will likely play a combinatorial role in the evolving management of SCI as the field continues to evolve.
CONTEXT: Spinal cord injury (SCI) is a devastating condition that can lead to significant neurological impairment and reduced quality of life. Despite advancements in our understanding of the pathophysiology and secondary injury mechanisms involved in SCI, there are currently very few effective treatments for this condition. The field, however, is rapidly changing as new treatments are developed and key discoveries are made. METHODS: In this review, we outline the pathophysiology, management, and long-term rehabilitation of individuals with traumatic SCI. We also provide an in-depth overview of emerging therapies along the spectrum of the translational pipeline. EVIDENCE SYNTHESIS: The concept of "time is spine" refers to the concept which emphasizes the importance of early transfer to specialized centers, early decompressive surgery, and early delivery of other treatments (e.g. blood pressure augmentation, methylprednisolone) to affect long-term outcomes. Another important evolution in management has been the recognition and prevention of the chronic complications of SCI including respiratory compromise, bladder dysfunction, Charcot joints, and pressure sores through directed interventions along with early integration of physical rehabilitation and mobilization. There have also been significant advances in neuroprotective and neuroregenerative strategies for SCI, many of which are actively in clinical trial including riluzole, Cethrin, stem cell transplantation, and the use of functional electrical stimulation. CONCLUSION: Pharmacologic treatments, cell-based therapies, and other technology-driven interventions will likely play a combinatorial role in the evolving management of SCI as the field continues to evolve.
Authors: Ryan P Salewski; Robert A Mitchell; Lijun Li; Carl Shen; Maria Milekovskaia; Andras Nagy; Michael G Fehlings Journal: Stem Cells Transl Med Date: 2015-05-15 Impact factor: 6.940
Authors: R John Hurlbert; Mark N Hadley; Beverly C Walters; Bizhan Aarabi; Sanjay S Dhall; Daniel E Gelb; Curtis J Rozzelle; Timothy C Ryken; Nicholas Theodore Journal: Neurosurgery Date: 2013-03 Impact factor: 4.654
Authors: Marcel F Dvorak; Vanessa K Noonan; Nader Fallah; Charles G Fisher; Joel Finkelstein; Brian K Kwon; Carly S Rivers; Henry Ahn; Jérôme Paquet; Eve C Tsai; Andrea Townson; Najmedden Attabib; Christopher S Bailey; Sean D Christie; Brian Drew; Daryl R Fourney; Richard Fox; R John Hurlbert; Michael G Johnson; A G Linassi; Stefan Parent; Michael G Fehlings Journal: J Neurotrauma Date: 2014-11-19 Impact factor: 5.269
Authors: A William Sheel; Wendy Darlene Reid; Andrea F Townson; Najib T Ayas; Kristin J Konnyu Journal: J Spinal Cord Med Date: 2008 Impact factor: 1.985
Authors: Ronald J Triolo; Stephanie Nogan Bailey; Michael E Miller; Lisa M Lombardo; Musa L Audu Journal: Arch Phys Med Rehabil Date: 2013-03-13 Impact factor: 3.966
Authors: Sang M Lee; Tae Y Yune; Sun J Kim; Do W Park; Young K Lee; Young C Kim; Young J Oh; George J Markelonis; Tae H Oh Journal: J Neurotrauma Date: 2003-10 Impact factor: 5.269
Authors: Dezhi Lu; Yang Yang; Pingping Zhang; Zhenjiang Ma; Wentao Li; Yan Song; Haiyang Feng; Wenqiang Yu; Fuchao Ren; Tao Li; Hong Zeng; Jinwu Wang Journal: Tissue Eng Regen Med Date: 2022-06-29 Impact factor: 4.169
Authors: Ibrahim Alnaami; Saleh Alsaleh; Mohammed S Al-Amri; Ayman Al-Alamri; Fares Al-Zahrani; Mohammed A Al-Amri; Mohammed Abid Khan Journal: J Family Med Prim Care Date: 2021-04-29